Publications in collaboration with researchers from German Center for Neurodegenerative Diseases (33)

2024

  1. EANM practice guidelines for an appropriate use of PET and SPECT for patients with epilepsy

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 51, Núm. 7, pp. 1891-1908

  2. Progress in the Treatment of Alzheimer’s Disease Is Needed – Position Statement of European Alzheimer’s Disease Consortium (EADC) Investigators

    Journal of Prevention of Alzheimer's Disease

2022

  1. Correction to: EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3 (European Journal of Nuclear Medicine and Molecular Imaging, (2022), 49, 2, (632-651), 10.1007/s00259-021-05603-w)

    European Journal of Nuclear Medicine and Molecular Imaging

  2. EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 49, Núm. 2, pp. 632-651

2021

  1. Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey

    International Journal of Geriatric Psychiatry, Vol. 36, Núm. 2, pp. 324-333

  2. Finding our way through the labyrinth of dementia biomarkers

    European Journal of Nuclear Medicine and Molecular Imaging

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias

    The Lancet Neurology, Vol. 19, Núm. 11, pp. 951-962

  2. Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (Acta Neuropathologica, (2019), 138, 2, (237-250), 10.1007/s00401-019-02026-8)

    Acta Neuropathologica

  3. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 47, Núm. 8, pp. 1885-1912

  4. Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis

    Scientific Reports, Vol. 10, Núm. 1

  5. Proven validity and management impact of amyloid imaging in Alzheimer’s disease—repetita juvant

    European Journal of Nuclear Medicine and Molecular Imaging

2019

  1. Genetic variation across RNA metabolism and cell death gene networks is implicated in the semantic variant of primary progressive aphasia

    Scientific Reports, Vol. 9, Núm. 1

  2. Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia

    Nature Medicine, Vol. 25, Núm. 1, pp. 152-164

  3. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System

    Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 11, pp. 301-309

2018

  1. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus

    European Journal of Neurology, Vol. 25, Núm. 10, pp. 1201-1217

  2. Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1557-1566

  3. CXCR4 involvement in neurodegenerative diseases

    Translational Psychiatry, Vol. 8, Núm. 1

  4. Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1534-1545

  5. Clinical utility of FDG-PET for the clinical diagnosis in MCI

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, Núm. 9, pp. 1497-1508